Nektar Therapeutics (NKTR) Q2 2026 Earnings Call: REZPEG Phase III Advances
Source Tradingkey
Key Takeaways
- Nektar Therapeutics ended Q2 2026 with $1.02 billion in cash and investments and no debt. Management said the cash runway extends into Q3 2028, beyond the initial Phase III atopic dermatitis readouts expected in mid-2028.
- Q2 noncash royalty revenue was $10.1 million. Net loss totaled $40.6 million, or $1.23 per basic and diluted share.
- The global ZENITH-AD Phase III program for rezpegaldesleukin, or REZPEG, began randomizing patients in July. The first two studies target biologic- and JAK inhibitor-naive patients, while a treatment-experienced study is scheduled to begin by the end of September 2026.
- Following discussions with the FDA, Nektar finalized a single 850-patient registrational Phase III study for REZPEG in alopecia areata. The company plans to start ZENITH-AA in early 2027 and expects data in the second half of 2029.
- Nektar raised its year-end 2026 cash and investments guidance to $815 million-$840 million. Full-year revenue guidance remains $40 million-$45 million.
- Upcoming clinical catalysts include REZOLVE-AA off-treatment data in Q4 2026, atopic dermatitis off-treatment data in Q1 2027 and initial data from the TrialNet-sponsored type 1 diabetes study in 2027.
Core Financial Data
| Metric | Q2 2026 / Period End | Guidance or Context |
|---|---|---|
| Cash and investments | $1.02 billion | No debt; expected runway into Q3 2028 |
| Public offering proceeds | Approximately $350 million | Net proceeds from April 2026 offering |
| Noncash royalty revenue | $10.1 million | 2026 revenue guidance remains $40 million-$45 million |
| R&D expense | $39.1 million | 2026 guidance of $210 million-$230 million |
| G&A expense | $12.8 million | 2026 guidance of $60 million-$65 million |
| Noncash interest expense | $7.2 million | 2026 guidance of approximately $30 million-$35 million |
| Net loss | $40.6 million | $1.23 per basic and diluted share |
| Year-end cash and investments | — | Raised to $815 million-$840 million |
Business and Operating Performance
REZPEG Phase III program in atopic dermatitis
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Alphabet (GOOGL) stock climbed about 3% on Monday. The trigger was a report from The Information that Google is building a new AI chip, called Frozen v2, to run its Gemini models up to 10 times more e
Nvidia reports Q2 earnings on August 26, and Wall Street already knows the headline number. Analysts expect about $92 billion in revenue and earnings per share of $2.08, double the year-ago figure.The
Reddit shares surged 11% in extended trading Thursday after S&P Dow Jones Indices confirmed the platform will join the S&P 500.Reddit is only the second pureplay social media stock in the benchmark in
Micron (MU) stock is holding near $911 after a 189% price rise in 2026. Yet, Wall Street still sees roughly 70% more upside. And there is good reason behind this optimism. The world is short of the me
SpaceX (SPCX) stock rose 12% on Wednesday to $149.29. That is a 36% gain in five sessions and more than $500 billion in new market value.The trigger was software, not rockets. SpaceXAI, the company’s
